RUNX1/RUNX1T1 FISH
Also known as: t(8;21) FISH, AML1/ETO FISH
Test category:
Oncology - Leukaemia
Use of test
Purpose:
Fusion of the AML1 and ETO genes defines a specific AML subtype. These two genes are also known as RUNX1 and RNX1T1 (respectively). This gene fusion is the result of a chromosomal translocation: t(8;21)(q22;q22). Identification of this fusion has prognostic implications.
Utility:
Fusion of AML1 and ETO is associated with favourable prognosis in adults with AML
Ethical considerations:
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Methodology:
Fluorescent in situ hybridisation (FISH) analysis, using probes designed to detect AML1-ETO gene fusion.
Requesting the test
Ordering:
This test is usually requested by a haematologist or oncologist.
Sample required:
0.5 mL bone marrow in transport media (or 10 mL blood in lithium heparin if blasts >10%).
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
Turnaround time:
2 business days.
Price:
This test has a Medicare rebate which, subject to the requirements of the Medicare descriptor being met, may cover all or part of the cost.
Rebate:
The Medicare details, including descriptor and schedule fee, are listed under MBS item 73314.